Business

For much of the past decade, the psychedelic industry has revolved around companies developing the drugs themselves. Psilocybin, MDMA, LSD...

Definium Therapeutics has reported a second positive Phase 3 trial of its LSD-based treatment for generalized anxiety disorder, strengthening the...

A growing group of companies is developing pharmaceutical-grade psilocybin from mushrooms, creating the infrastructure needed to investigate whether the broader...

Entropy Neurodynamics has reported sustained improvements in treatment-resistant binge-eating disorder three months after patients received two infusions of its IV...

Australian psychedelic medicine company Emyria Limited (ASX: EMD) has been selected by the US Food and Drug Administration (FDA) to...

Emyria (ASX: EMD) is preparing to open its first Sydney clinic in September, with the company saying key operational milestones...

BLS Pharmaceuticals Limited (ASX: BLS) has appointed Zivana Crestani as Strategic Partnership Director, adding to the company's commercial leadership as...

Australia's listed cannabis sector has become increasingly difficult to define simply as "cannabis". The latest results show companies moving in...

BLS Pharmaceuticals (ASX: BLS) has reported a record FY26, with revenue climbing 161% to $74.2 million and Adjusted EBITDA rising...

The psychedelic industry has no shortage of drug developers, clinical trials or investment pitches. What it has less of is...